IP Library Granted Patent US 8,221,800
Granted Patent B2
US 8,221,800 · App. 11/279,029 · Granted Jul 17, 2012

Nitric oxide delivery system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,221,800
App. No.
11/279,029
Granted
Jul 17, 2012
Kind
B2
Abstract

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. Precise delivery of nitric oxide at therapeutic levels of 20 to 100 ppm and inhibition of reaction of nitric oxide with oxygen to form toxic impurities such as nitrogen dioxide can provide effective inhalation therapy for pulmonary hypertension.

Claims (7)

1. A kit comprising a solution of a nitric oxide precursor that includes a precursor salt, a cathode and an anode disposed within the solution and instructional material describing a method of generating a therapeutic gas wherein the method includes applying a voltage across the cathode and anode to generate the therapeutic gas and transporting the therapeutic gas, the therapeutic gas comprising nitric oxide and being substantially devoid of nitrogen dioxide.

2. The kit of claim 1 wherein the precursor salt includes a nitrite salt.

3. The kit of claim 1 wherein the precursor salt includes a nitrite salt selected from a group consisting of potassium nitrite, sodium nitrite, rubidium nitrite, strontium nitrite, barium nitrite, calcium nitrite, copper nitrite and zinc nitrite.

4. The kit of claim 3 wherein the nitrite salt includes sodium nitrite.

5. The kit of claim 1 wherein generating the therapeutic gas includes releasing nitric oxide from the precursor over a period of time from one hour to seven days.

6. The kit of claim 5 wherein generating the therapeutic gas includes releasing nitric oxide from the precursor over a period of time from two hours to 24 hours.

7. The kit of claim 1 wherein generating the therapeutic gas includes releasing nitric oxide for at least one hour.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Aug 7, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 048173/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2006
From: FINE, DAVID H.; MACDONALD, STEPHEN J.; ROUNBEHLER, DAVID; WHEELER, DAVID; ROLFE, JONATHAN L.; JARVIS, GEORGE
To: GENO LLC
Reel/Frame 017447/0561 →